Trial Profile

Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TC 110 (Primary) ; Cyclophosphamide; Fludarabine
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors TCR2 Therapeutics

Most Recent Events

14 Mar 2023 Status changed from recruiting to completed.
13 May 2021 According to a TCR2 Therapeutics media release, the company anticipates interim update in the second half of 2021.
12 Nov 2020 According to a TCR2 Therapeutics media release, the company anticipates an interim update from the Phase 1 portion of the study for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com